Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Sebetralstat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sebetralstat is expected to reach an annual total of $203 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sebetralstat Overview
Sebetralstat (KVD-900) is under development for the treatment of hereditary angioedema. The drug candidate is administered through oral route in the form of the tablet. It acts by targeting plasma kallikrein.
See Also:
Kalvista Pharmaceuticals Overview
Kalvista Pharmaceuticals, Inc. is a pharmaceutical company that is into the discovery, development, and commercialization of oral, small-molecule protease inhibitors for diseases with significant unmet needs. The company’s product pipeline includes sebetralstat, oral factor Xlla and KVD001. Its pipeline candidates treat hereditary angioedema, prophylaxis in hereditary angioedema, thrombosis inflammation and diabetic macular edema. Kalvista is also progressing additional oral candidates toward regulatory preclinical studies. The company has its operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$110.9 million in FY2023, compared to an operating loss of US$96.6 million in FY2022. The net loss of the company was US$92.9 million in FY2023, compared to a net loss of US$82.3 million in FY2022.
For a complete picture of Sebetralstat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.